ReviewNature reviews. Nephrology2015
Phosphate and FGF-23 homeostasis after kidney transplantation.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07415421 (Subtotal Parathyroidectomy for the Treatment of Persistent Hyperparathyroidism After Kidney Transplantation), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Subtotal Parathyroidectomy for the Treatment of Persistent Hyperparathyroidism After Kidney Transplantation
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines.BMC medicine · 2025Pooled it
- Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.Medicine · 2016Trial
- Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.Kidney international reports · 2026Review
- Endothelial dysfunction in the kidney transplant population: Current evidence and management strategies.World journal of transplantation · 2025Review
- Bone health and fracture prevention after kidney transplantation.Journal of clinical & translational endocrinology · 2024Review
- Pre-Transplant Hyperparathyroidism and Graft or Patient Outcomes After Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Calcification Propensity (T50) Predicts a Rapid Decline of Renal Function in Kidney Transplant Recipients.Journal of clinical medicine · 2023Article
- [Pattern of biochemical markers of mineral and bone disorders in kidney transplant recipients: real-world data].Problemy endokrinologii · 2023Article
- Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet.Drugs in context · 2023Article
- An unusual cause of elevated serum creatinine after kidney transplantation in an adolescent: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Bone and Mineral Disease in Kidney Transplant Recipients.Clinical journal of the American Society of Nephrology : CJASN · 2022Review
- Clinical factors associated with severe hypophosphataemia after kidney transplant.BMC nephrology · 2021Observational
- Phosphate and fibroblast growth factor 23 in diabetes.Clinical science (London, England : 1979) · 2021Review
- Association of time-updated plasma calcium and phosphate with graft and patient outcomes after kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- New Therapies for Hypophosphatemia-Related to FGF23 Excess.Calcified tissue international · 2021Review
- The Causes of Hypo- and Hyperphosphatemia in Humans.Calcified tissue international · 2021Review
- CKD-MBD post kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2021Article
- Causes of hypercalcemia in renal transplant recipients: persistent hyperparathyroidism and others.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Association between Uremic Toxin Concentrations and Bone Mineral Density after Kidney Transplantation.Toxins · 2020Article
- Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.Current diabetes reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated phosphate metabolism is a common consequence of chronic kidney disease, and is characterized by a high circulating level of fibroblast growth factor (FGF)-23, hyperparathyroidism, and hyperphosphataemia. Kidney transplantation can elicit specific alterations to phosphate metabolism that evolve over time, ranging from severe hypophosphataemia (<0.5 mmol/l) to hyperphosphataemia (>1.50 mmol/l) and high FGF-23 levels. The majority of renal transplant recipients develop hypophosphataemia during the first 3 months after transplantation as a consequence of relatively slow adaptation of FGF-23 and parathyroid hormone levels to restored renal function, and the influence of immunosuppressive drugs. By 3-12 months after transplantation, phosphate homeostasis is at least partially restored in the majority of recipients, which is paralleled by a substantially reduced risk of cardiovascular-associated morbidity and mortality compared with the pre-transplantation setting. Many renal transplant recipients, however, exhibit persistent abnormalities in phosphate homeostasis, which is often due to multifactorial causes, and may contribute to adverse outcomes on the cardiovascular system, kidney, and bone. Dietary and pharmacologic interventions might improve phosphate homeostasis in renal transplant recipients, but additional insight into the pathophysiology of transplantation-associated abnormalities in phosphate homeostasis is needed to further optimize disease management and improve prognosis for renal transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.